Wednesday, 18 October 2017
Latest news
Main » Paloma Partners Management Co Raises Stake in Opko Health, Inc. (NASDAQ:OPK)

Paloma Partners Management Co Raises Stake in Opko Health, Inc. (NASDAQ:OPK)

06 July 2017

Analysts reported that the Price Target for Opko Health, Inc. might touch $19.5 high while the Average Price Target and Low price Target is $13.5 and $8 respectively. Zacks Investment Research downgraded Opko Health from a "hold" rating to a "sell" rating in a research report on Thursday, May 4th. Consensus earnings estimates are far from flawless, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. Wall Street analysts have a consensus 1.80 recommendation on the stock. The company maintains price to book ratio of 1.75 vs.an industry average at 4.58.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings data on Tuesday, May 9th.

In the market the company is trading unchanged by 0.00 percent from yesterday's close.

More news: Watch SpaceX's Intelsat 35e launch live right here

Gilead Sciences, Inc. (NASDAQ:GILD), stock is trading $88.85 above the 52-week high and has displayed a high EPS growth of 41.20% in last 5 years. Company chares are trading at $6.58 which is just under the 50 day moving average which is $6.59 and a bit lower than the 200 day moving average of $8.10. Its last month's stock price volatility remained 4.19% which for the week stands at 3.88%. Ladenburg Thalmann Financial Services restated a "buy" rating and set a $19.50 target price on shares of Opko Health in a research note on Friday, June 16th.

As of the last earnings report the EPS was $-0.08 and is projected to be $-0.20 for the current year with 559,388,000 shares presently outstanding. The Return on Equity (ROE) value stands at -2.1%. The company had revenue of $296.10 million for the quarter, compared to analyst estimates of $313.36 million. During the same period in the previous year, the business posted ($0.02) EPS. Opko Health's revenue for the quarter was up 1.8% on a year-over-year basis.

Stock of Opko Health, Inc.

More news: Turkey Opposes Berlin Art Installation Calling Erdogan a Dictator

OPK has been the topic of a number of recent research reports. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & worldwide copyright and trademark legislation.

In related news, Director Richard A. Lerner purchased 10,000 shares of the firm's stock in a transaction dated Monday, June 5th. Institutional owners hold 23.80% stake in the company while Insiders ownership held at 6.80%. Stocks with a beta value over 1 have historically been more volatile than the overall market. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The Company has 52-week high of $12.15 and 52-week low of $5.99. When the opening bell rang, the price was $6.53. Whalerock Point Partners LLC now owns 220,800 shares of the biotechnology company's stock valued at $2,053,000 after buying an additional 22,425 shares during the last quarter. The disclosure for this purchase can be found here. The stock sank -4.17% last month and is down -30.86 this year.

Several hedge funds have recently made changes to their positions in the stock. As of quarter end Mivtachim The Workers Social Insurance Fund Ltd. Bank of Montreal Can raised its position in shares of Opko Health by 1.4% in the first quarter. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. Finally, RK Asset Management LLC increased its stake in shares of Opko Health by 0.4% in the first quarter. Following the transaction, the insider now owns 24,723,133 shares in the company, valued at approximately $172,320,237.01. Investors bought 1,610 put options on the company.

More news: Explosion near Eglins's climate lab sends plume of smoke into air

OPKO Health, Inc is a healthcare company.